Australia approves Wegovy weight-loss tablets; compares pill vs. injection

Consensus Summary

Australia’s Therapeutic Goods Administration (TGA) approved Wegovy weight-loss tablets in four strengths—1.5mg, 4mg, 9mg, and 25mg—on Tuesday, marking the first GLP-1 medication in pill form for weight management. The tablets, manufactured by Novo Nordisk, will be available by the end of the year, offering an alternative to weekly injections for those who prefer oral medication or struggle with needles. The approval follows a surge in demand for weight-loss drugs globally, with three million prescriptions for Wegovy issued in the US within the first five months of its launch there this year. The tablets contain 25 milligrams of semaglutide, compared to 2.4 milligrams in the injection, reflecting the body’s lower absorption rate when taken orally.

The development comes as Australia grapples with rising demand for GLP-1 medications, which have gained popularity for their effectiveness in weight loss and cardiovascular risk reduction. Until now, these drugs—including Wegovy and Ozempic—have been available only as weekly injections, creating logistical challenges for patients. The TGA’s approval of the tablet form is expected to expand access, particularly for those who dislike injections or face difficulties administering them. However, the tablets require daily use on an empty stomach, with a 30-minute wait before eating or drinking, adding a new layer of adherence demands compared to the once-weekly injection regimen.

Healthcare providers and patients have welcomed the new option, though concerns remain about side effects and long-term efficacy. The ABC reports that both tablet and injection forms show similar weight loss outcomes—14% for the pill and 15% for the injection over 64–68 weeks—but emphasize that the pill’s effectiveness depends on consistent daily use. Dr. Ginni Mansberg, a general practitioner quoted by 7NEWS, noted that while the pill may be a ‘game changer’ for needle-averse patients, side effects remain comparable to the injection. Patients like Linzi Ibrahim, who lost 15 kilos in 12 months on Wegovy, highlight the drug’s life-changing benefits, including improved blood pressure and asthma. Pharmacists predict a 40% surge in weight-loss drug use following the pill’s approval, though pricing remains uncertain—ranging from US$150 to US$300 a month in the US.

While the ABC and Guardian agree on the timeline for availability—by the end of the year or Christmas—they differ slightly in framing the rollout. The ABC underscores the need for further TGA review of packaging and production before release, while the Guardian specifies a Christmas launch. The ABC also notes that the tablets are not yet subsidized under Australia’s Pharmaceutical Benefits Scheme (PBS), meaning patients will initially bear the full cost, similar to the injection’s A$250–$450 monthly price. Meanwhile, 7NEWS highlights the cost advantage in the US, where the pill is slightly cheaper than the injection despite containing more semaglutide. The approval also raises questions about equitable access, as calls grow for PBS listing to support those with serious obesity or related health conditions.

Uncertainties remain about the tablet’s long-term impact, including whether it will reduce the strain on needle and syringe programs overwhelmed by demand for injections. The ABC warns that rapid weight loss can lead to muscle loss and rebound weight gain if patients stop the medication without lifestyle changes, citing research where participants regained two-thirds of lost weight within a year of cessation. Doctors stress that the drug is intended for those with obesity or cardiovascular risks, not cosmetic weight loss. As Novo Nordisk prepares for the Australian launch, the TGA’s final review of packaging and production will determine the exact timeline, with the Guardian’s ‘by Christmas’ deadline adding a sense of urgency to the rollout.